share_log

Needham Maintains Buy on TransMedics Gr, Lowers Price Target to $109

Benzinga ·  Oct 29 18:39  · Ratings

Needham analyst Mike Matson maintains TransMedics Gr (NASDAQ:TMDX) with a Buy and lowers the price target from $208 to $109.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment